Peptide Schedule
Bonomarlot6 residuesAEDRVGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Bonomarlot Dosage Calculator
Bonomarlot is a peptide bioregulator developed at the St.
10mcg · Daily
Summary: Add 0mL BAC water to your 20mg vial. Draw to < 0.1 units on a U-100 syringe for a 10mcg dose. This vial will last 0 doses.
Cycle Planner
Bonomarlot Pharmacokinetics
Bonomarlot Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | 2x Daily |
Note: Bonomarlot (A-20) is a Khavinson-class Cytomax bioregulator derived from bovine bone marrow tissue. It contains short peptides (2-7 amino acids) intended to target bone marrow gene expression. Standard protocol is 2 capsules daily for 10-30 days, repeated every 3-6 months. This is an oral capsule product — no reconstitution or injection is needed. Evidence is limited to the broader Khavinson bioregulator research program; there are no Bonomarlot-specific clinical trials indexed in PubMed.
About Bonomarlot
Bonomarlot is a peptide bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson's research program. It's derived from bovine bone marrow tissue and contains short-chain peptides typically 2-7 amino acids in length. The product is classified as part of the Cytomax line of tissue-specific bioregulators and carries the designation A-20. Bone marrow serves as the primary site of hematopoiesis — the production of red blood cells, white blood cells, and platelets from hematopoietic stem cells. It's also home to mesenchymal stem cells that can differentiate into bone, cartilage, and fat tissue. Age-related decline in bone marrow function contributes to immunosenescence, anemia, and reduced regenerative capacity. Bonomarlot's proposed function is to restore normal gene expression patterns in bone marrow tissue by delivering tissue-specific peptide fragments. Khavinson's broader research program has shown that short peptides can enter cell nuclei, interact with histone proteins and DNA promoter regions, and influence transcription. Related peptides like AED, KED, and KE have been studied in human bone marrow mesenchymal stem cells, where they modulated expression of senescence-related genes including IGF1, FOXO1, and TERT. No peer-reviewed clinical trials specific to Bonomarlot have been published. The product's theoretical basis rests on Khavinson's general bioregulator research and separate myelopeptide studies by Petrov and colleagues, which identified immunoregulatory hexapeptides produced by bone marrow cells.